California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.
For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
